The aim of this study was to compare the serum levels of the anti-angiogenic factor endostatin (S-endostatin) as a potential marker of vasculogenesis after autologous cell therapy (ACT) versus percutaneous transluminal angioplasty (PTA) in diabetic patients with critical limb ischemia (CLI). A total of 25 diabetic patients with CLI treated in our foot clinic during the period 2008-2014 with ACT generating potential vasculogenesis were consecutively included in the study; 14 diabetic patients with CLI who underwent PTA during the same period were included in a control group in which no vasculogenesis had occurred. S-endostatin was measured before revascularization and at 1, 3, and 6 months after the procedure. The effect of ACT and PTA on tissue ischemia was confirmed by transcutaneous oxygen pressure (TcPO2) measurement at the same intervals. While S-endostatin levels increased significantly at 1 and 3 months after ACT (both P < 0.001), no significant change of S-endostatin after PTA was observed. Elevation of S-endostatin levels significantly correlated with an increase in TcPO2 at 1 month after ACT ( r = 0.557; P < 0.001). Our study showed that endostatin might be a potential marker of vasculogenesis because of its significant increase after ACT in diabetic patients with CLI in contrast to those undergoing PTA. This increase may be a sign of a protective feedback mechanism of this anti-angiogenic factor.

Department of Immunogenetics Institute for Clinical and Experimental Medicine Prague Czech Republic

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Diabetes Centre Tameside Hospital NHS Foundation Trust and University of Manchester Lancashire UK

See more in PubMed

Dua A, Lee CJ. Epidemiology of peripheral arterial disease and critical limb ischemia. Tech Vasc Interv Radiol. 2016;19(2):91–5. PubMed

Brownrigg JR, Schaper NC, Hinchliffe RJ. Diagnosis and assessment of peripheral arterial disease in the diabetic foot. Diabet Med. 2015;32(6):738–47. PubMed

Benitez E, Sumpio BJ, Chin J, Sumpio BE. Contemporary assessment of foot perfusion in patients with critical limb ischemia. Semin Vasc Surg. 2014;27(1):3–15. PubMed

Compagna R, Amato B, Massa S, Amato M, Grande R, Butrico L, de Franciscis S, Serra R. Cell therapy in patients with critical limb ischemia. Stem Cells Int. 2015:931420. PubMed PMC

Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28(9):2155–60. PubMed

Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209(1):10–17. PubMed

Liu Y, Xu Y, Fang F, Zhang J, Guo L, Weng Z. Therapeutic efficacy of stem cell-based therapy in peripheral arterial disease: A meta-analysis. PLoS One. 2015;10(4): e01250 32. PubMed PMC

Ai M, Yan CF, Xia FC, Zhou SL, He J, Li CP. Safety and efficacy of cell-based therapy on critical limb ischemia: A meta-analysis. Cytotherapy. 2016;18(6):712–24. PubMed

Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther. 2005;12(6):994–1005. PubMed

Li S, Zhou B, Han ZC. Therapeutic neovascularization by transplantation of mobilized peripheral blood mononuclear cells for limb ischemia. A comparison between CD34+ and CD34– mononuclear cells. Thromb Haemost. 2006;95(2):301–11. PubMed

Mackie AR, Losordo DW. . CD34-positive stem cells: In the treatment of heart and vascular disease in human beings. Tex Heart Inst J. 2011;38(5):474–85. PubMed PMC

Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A. Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes. Diabetes Care. 2017;40(1):125–31. PubMed

Zubair AC, Malik S, Paulsen A, Ishikawa M, McCoy C, Adams PX, Amrani D, Costa M. Evaluation of mobilized peripheral blood CD34(+) cells from patients with severe coronary artery disease as a source of endothelial progenitor cells. Cytotherapy. 2010;12(2):178–89. PubMed PMC

Hristov M, Weber C. Progenitor cell trafficking in the vascular wall. J Thromb Haemost. 2009;7(Suppl 1):31–34. PubMed

Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: Two mechanisms of vessel growth. News Physiol Sci. 1999;14:121–5. PubMed

Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: Angiogenic and cell therapies. Circ Res. 2015;116(9):1561–78. PubMed PMC

Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost. 2010;103(4):696–709. PubMed

Aranguren XL, Verfaillie CM, Luttun A. Emerging hurdles in stem cell therapy for peripheral vascular disease. J Mol Med (Berl). 2009;87(1):3–16. PubMed

Dubsky M, Jirkovska A, Bem R, Fejfarova V, Varga M, Kolesar L, Pagacova L, Sykova E, Jude EB. Role of serum levels of angiogenic cytokines in assessment of angiogenesis after stem cell therapy of diabetic patients with critical limb ischemia. Cell Transplant. 2014;23(12):1517–23. PubMed

Di Vita G, Patti R, D’Agostino P, Arcoleo F, Caruso G, Arcara M, Davi V, Cillari E. Serum VEGF and B-FGF profiles after tension-free or conventional hernioplasty. Langenbecks Arch Surg. 2005;390(6):528–33. PubMed

Kinnaird T, Stabile E, Burnett MS, Epstein SE. Bone-marrow-derived cells for enhancing collateral development: Mechanisms, animal data, and initial clinical experiences. Circ Res. 2004;95(4):354–63. PubMed

Ribatti D. Endogenous inhibitors of angiogenesis: A historical review. Leuk Res. 2009;33(5):638–44. PubMed

Poluzzi C, Iozzo RV, Schaefer L. Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers. Adv Drug Deliv Rev. 2016;97:156–73. PubMed PMC

Walia A, Yang JF, Huang YH, Rosenblatt MI, Chang JH, Azar DT. Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta. 2015;1850(12):2422–38. PubMed PMC

Wang H, Chen Y, Lu XA, Liu G, Fu Y, Luo Y. Endostatin prevents dietary-induced obesity by inhibiting adipogenesis and angiogenesis. Diabetes. 2015;64(7):2442–56. PubMed

Carlsson AC, Ostgren CJ, Lanne T, Larsson A, Nystrom FH, Arnlov J. The association between endostatin and kidney disease and mortality in patients with type 2 diabetes. Diabetes Metab. 2016;42(5):351–7. PubMed

Ruge T, Carlsson AC, Larsson A, Arnlov J. Endostatin: A promising biomarker in the cardiovascular continuum? Biomark Med. 2017;11(10):905–16. PubMed

Al Mheid I, Quyyumi AA. Cell therapy in peripheral arterial disease. Angiology. 2008;59(6):705–16. PubMed

Dubsky M, Jirkovska A, Bem R, Fejfarova V, Pagacova L, Nemcova A, Sixta B, Chlupac J, Peregrin JH, Sykova E, Jude EB. Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia. Cytotherapy. 2014;16(12):1733–8. PubMed

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Group TIW, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(Suppl 1): S1–75. PubMed

Graziani L, Silvestro A, Bertone V, Manara E, Andreini R, Sigala A, Mingardi R, De Giglio R. Vascular involvement in diabetic subjects with ischemic foot ulcer: A new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg. 2007;33(4):453–60. PubMed

Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP, Jr., Folkman J, Soker S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003;63(23):8345–50. PubMed

Fu Y, Tang H, Huang Y, Song N, Luo Y. Unraveling the mysteries of endostatin. IUBMB Life. 2009;61(6):613–26. PubMed

Folkman J. Antiangiogenesis in cancer therapy: endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594–607. PubMed

Xue L, Chen H, Zhang T, Chen J, Geng Z, Zhao Y. Changes in serum vascular endothelial growth factor and endostatin concentrations associated with circulating endothelial progenitor cells after acute ischemic stroke. Metab Brain Dis. 2017;32(2):641–8. PubMed

Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, Fukushima M, Asahara T. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: A phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009;27(11):2857–64. PubMed

Dong Z, Chen B, Fu W, Wang Y, Guo D, Wei Z, Xu X, Mendelsohn FO. Transplantation of purified CD34+ cells in the treatment of critical limb ischemia. J Vasc Surg. 2013;58(2):404–411 e403. PubMed

Madaric J, Klepanec A, Valachovicova M, Mistrik M, Bucova M, Olejarova I, Necpal R, Madaricova T, Paulis L, Vulev I. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia. Stem Cell Res Ther. 2016;7(1):116. PubMed PMC

Qin Q, Qian J, Ma J, Ge L, Ge J. Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion. Medicine (Baltimore). 2016;95(33): e4524. PubMed PMC

Golledge J, Clancy P, Hankey GJ, Yeap BB, Norman PE. Serum endostatin concentrations are higher in men with symptoms of intermittent claudication. Dis Markers. 2014:298239. PubMed PMC

Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res. 2004;94(2):230–8. PubMed

Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patients with chronic limb-threatening ischemia: A randomized controlled trial